2021 marks fourth consecutive year Quanterix was recognized on the Deloitte Technology Fast 500 BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 17, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today

Ultra-sensitive Simoa ® technology highlights the important potential of plasma biomarkers to enable drug trials focusing on patients at an earlier stage of disease and to facilitate accelerated and more efficient trial enrollment BILLERICA, Mass. --(BUSINESS WIRE)--Nov.

BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 11, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that members of its executive leadership team will participate in a virtual fireside chat discussion at the

Northwestern University’s prestigious biennial award honors those who have made a lasting impact in the field of nanotechnology BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 8, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of

Third quarter revenue driven by unprecedented growth in consumables (+98% vs PY) and instruments (+44% vs PY) BILLERICA, Mass. --(BUSINESS WIRE)--Nov. 4, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health,

BILLERICA, Mass. --(BUSINESS WIRE)--Oct. 28, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will release its financial results for third quarter 2021 after the close of trading on Nov.

BILLERICA, Mass. --(BUSINESS WIRE)--Oct. 11, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, announced today that its Simoa® phospho-Tau 181 (pTau-181) blood test has been granted Breakthrough Device

Live webinar discussion explored the benefits of ultra-sensitive detection for asymptomatic COVID-19 patients and highlighted linkages to other areas of human health BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 20, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis

Simoa SARS-CoV-2 N Protein Antigen Test is first antigen test validated to detect all Variants of Concern currently designated by CDC , including Delta variant, and first authorized for use in saliva samples EUA label expansion demonstrates additional evidence showing potential for Simoa technology

BILLERICA, Mass. --(BUSINESS WIRE)--Sep. 10, 2021-- Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced a webinar hosted by Kevin Hrusovsky , Quanterix Chairman and Chief Executive Officer, with